Am J Cardiovasc Drugs (2018) 18:103–108 https://doi.org/10.1007/s40256-017-0246-z ORIGINAL RESEARCH ARTICLE Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors 1 1 1 2 • • • • Pallavi B. Rane Jeetvan Patel David J. Harrison Jason Shepherd 2 2 2 • • Andrea Leith Hollie Bailey James Piercy Published online: 28 August 2017 Springer International Publishing AG 2017 Abstract use was reported in 69.1% of PCSK9i patients and 19.5% Background Proprotein convertase subtilisin/kexin type 9 of non-PCSK9i patients, and physician-reported statin inhibitors (PCSK9i) reduce low-density lipoprotein choles- intolerance was observed in 31.6% of PCSK9i and 5.3% of terol (LDL-C) levels and are approved for patients with non-PCSK9i patients. Use of statins only was reported in familial hypercholesterolemia or atherosclerotic cardiovas- 40.5% of PCSK9i and 88.8% of non-PCSK9i patients. The cular disease who require additional LDL-C lowering. most common physician-reported reasons for change to Objective Our objective was to characterize patients PCSK9i were lack of efﬁcacy (70.2%) and muscle-related receiving PCSK9i medications in real-world practice and symptoms (myalgia 28.6%; myopathy 11.1%). describe physician-reported treatment patterns among Conclusions Physicians surveyed appeared to prescribe dyslipidemia patients using PCSK9i or other lipid-lowering PCSK9i medications appropriately. PCSK9i-treated therapy. patients had higher
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera